Multiplex Ligation-dependent Probe Amplification Can Clarify HER2 Status in Gastric Cancers with “Polysomy 17”

Therapy with trastuzumab confers a survival benefit in HER2 positive advanced gastric and gastroesophageal adenocarcinoma. HER2 status is evaluated by immunohistochemistry (IHC) and in situ hybridization (ISH). An ISH ratio of HER2 to centromere 17 (CEP17) ≥2.0 is considered amplified. This assumes...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tao, Amemiya, Yutaka, Henry, Pauline, Seth, Arun, Hanna, Wedad, Hsieh, Eugene T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392047/
https://www.ncbi.nlm.nih.gov/pubmed/25874002
http://dx.doi.org/10.7150/jca.11424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392047/
https://www.ncbi.nlm.nih.gov/pubmed/25874002
http://dx.doi.org/10.7150/jca.11424

Ejemplares similares